Stephen is currently CSO and COO of Karus Therapeutics and is the founding scientist of the PI3K-p110β/δ and HDAC6 programs. He led the development of oral small molecule anti-tumour agents from concept to Phase I clinical trials. In January 2019, Stephen was also appointed entrepreneur-in-residence at Samsara BioCapital, California.

Stephen obtained his BSc and PhD in Chemistry from the University of Liverpool, has published extensively, and has been an invited speaker at multiple international conferences. In 2007 he was appointed a Fellow of the Royal Society of Chemistry, and in 2014 an Honorary Professor (Molecular & Clinical Cancer Sciences, School of Medical Science) at the University of Manchester.

James Culverwell, chairman of HOX Therapeutics, said: “We are delighted to welcome Stephen to the Board. His extensive experience in drug discovery and development in oncology will be invaluable as we progress our lead asset into clinical development later this year.”